HART Regains Compliance With Nasdaq Minimum Bid Price Listing Rule

Loading...
Loading...
Harvard Apparatus Regenerative Technology, Inc. (HART)
HART
today announced it has received written notification from The NASDAQ Stock Market that it has regained compliance with the minimum bid price requirements. The letter noted that as a result of the closing bid price of HART's common stock having exceeded $1.00 per share for more than ten consecutive business days, the company has regained compliance and the matter is now closed. HART's CEO, Jim McGorry, commented, "Maintaining our NASDAQ listing is fundamental to our corporate strategy. We are gratified by the investment community's response to our recent progress, including the positive animal research results on HART's second generation (Gen2) bioengineered esophageal, tracheal and bronchial implants." Mr. McGorry continued, "Going forward, our development plan is focused on getting our technology back into humans on a compassionate use basis and filing our first clinical trial application with the FDA during 2016. We are confident that we will meet these goals given the results of our recent studies using our Gen2 technology across all three applications, our strong scientific team and our collaborations with translational partners. We have initiated
See full press release
Posted In: NewsPress Releases
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...